Our results indicate that EF-2001 administration decreases liver damage by reducing the physical size of the HFD-induced fatty liver and lowering the levels of enzymes, such as GOT and GPT, released in the blood following liver damage. The gene discussed is GPT; the disease is Hepatic steatosis.